Trial · NCT05134532
Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC
NCT05134532, Phase 2, Unknown, CHA University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC. Trials, record NCT05134532. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05134532
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC
- NCT number
- NCT05134532
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- CHA University
- Conditions
- Hepatocellular Carcinoma
- Interventions
- regorafenib
- First posted
- 2021-11-26
- Last updated
- 2023-04-26
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) by RECIST v 1.1 | up to 36 months | the time from start of study treatment to first documentation of objective tumor progression, or to death due to any cause |
| Secondary | Overall survival | up to 36 months | the time from start of study treatment to date of death due to any cause |
| Secondary | Time to progression by RECIST v 1.1 | up to 36 months | the time from start of study (Cycle 1 Day 1) to first documentation of objective tumor progression. |
| Secondary | Overall response rate by RECIST v 1.1 | up to 36 months | the proportion of patients with confirmed complete response or confirmed partial response according to the RECIST v 1.1, relative to the total evaluable patient population. |
| Secondary | Disease control rate by RECIST v 1.1 | up to 36 months | the percent of patients with confirmed complete response, partial response, or stable disease for at least 12 weeks on study according to RECIST v 1.1, relative to the total evaluable patient population. |
| Secondary | Safety profiles by NCI-CTCAE version 5 | up to 36 months | For the evaluation of adverse reactions following medication, using NCI-CTCAE version 5 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05134532
GET https://conductscience.org/api/trials/v1/NCT05134532/registered